- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
ALLEGAN, Mich. — Following the warning letter it received last April, Perrigo announced that the Food and Drug Administration has arrived at the company's Allegan, Mich.-based facility for re-inspection.
The re-inspection of the plant follows an initial inspection that occurred between Nov. 17, 2009, and Jan. 14, 2010, in which the FDA "identified significant violations of current good manufacturing practice regulations for finished pharmaceuticals," the regulatory agency said in its letter last year, noting certain production problems, including an equipment failure that shredded metal shavings into bottles on a production line of 200-mg ibuprofen tablets.